| Name | Title | Contact Details |
|---|
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
International Center for Toxicology and Medicine is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Resau Medisca Network Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MBC Pharma (Main) is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant`s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.